173 related articles for article (PubMed ID: 34848441)
21. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
[TBL] [Abstract][Full Text] [Related]
22. Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma.
Higuchi T; Oshiro H; Miyake K; Sugisawa N; Han Q; Tan Y; Park J; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Chawla SP; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2019 Sep; 39(9):4653-4657. PubMed ID: 31519563
[TBL] [Abstract][Full Text] [Related]
23. Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
Igarashi K; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Nelson SD; Dry SM; Li Y; Yanagawa J; Russell TA; Singh AS; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jun; 16(12):1164-1170. PubMed ID: 28494180
[TBL] [Abstract][Full Text] [Related]
24. The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
Wu NF; Yamamoto J; Aoki Y; Masaki N; Samonte C; Wu J; Bouvet M; Hoffman RM
Anticancer Res; 2021 Oct; 41(10):4715-4718. PubMed ID: 34593419
[TBL] [Abstract][Full Text] [Related]
25. Patient-derived orthotopic xenograft models of sarcoma.
Igarashi K; Kawaguchi K; Murakami T; Miyake K; Kiyuna T; Miyake M; Hiroshima Y; Higuchi T; Oshiro H; Nelson SD; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
Cancer Lett; 2020 Jan; 469():332-339. PubMed ID: 31639427
[TBL] [Abstract][Full Text] [Related]
26. Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model.
Kiyuna T; Tome Y; Murakami T; Kawaguchi K; Igarashi K; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Russell TA; Elliott I; Singh SR; Kanaya F; Eilber FC; Hoffman RM
BMC Cancer; 2018 Aug; 18(1):840. PubMed ID: 30126369
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
Oncotarget; 2018 Jan; 9(8):7774-7781. PubMed ID: 29487690
[TBL] [Abstract][Full Text] [Related]
28. A Novel Procedure for Orthotopic Tibia Implantation for Establishment of a More Clinical Osteosarcoma PDOX Mouse Model.
Wu NF; Yamamoto J; Bouvet M; Hoffman RM
In Vivo; 2021; 35(1):105-109. PubMed ID: 33402455
[TBL] [Abstract][Full Text] [Related]
29. A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology.
Igarashi K; Murakami T; Kawaguchi K; Kiyuna T; Miyake K; Zhang Y; Nelson SD; Dry SM; Li Y; Yanagawa J; Russell TA; Singh AS; Tsuchiya H; Elliott I; Eilber FC; Hoffman RM
Oncotarget; 2017 Sep; 8(37):62111-62119. PubMed ID: 28977930
[TBL] [Abstract][Full Text] [Related]
30. High Clinical Concordance of Drug Resistance in Patient-derived Orthotopic Xenograft (PDOX) Mouse Models: First Step to Validated Precise Individualized Cancer Chemotherapy.
Higuchi T; Yamamoto N; Hayashi K; Miwa S; Igarashi K; Tsuchiya H; Hoffman RM
Anticancer Res; 2023 Oct; 43(10):4277-4284. PubMed ID: 37772554
[TBL] [Abstract][Full Text] [Related]
31. Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model.
Masaki N; Han Q; Samonte C; Wu NF; Hozumi C; Wu J; Obara K; Kubota Y; Aoki Y; Bouvet M; Hoffman RM
Anticancer Res; 2022 Nov; 42(11):5217-5222. PubMed ID: 36288875
[TBL] [Abstract][Full Text] [Related]
32. Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model.
Oshiro H; Tome Y; Kiyuna T; Miyake K; Kawaguchi K; Higuchi T; Miyake M; Zang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Nelson SD; Li Y; Bouvet M; Singh SR; Kanaya F; Hoffman RM
Tissue Cell; 2019 Jun; 58():17-23. PubMed ID: 31133242
[TBL] [Abstract][Full Text] [Related]
33. Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.
Murakami T; Igarashi K; Kawaguchi K; Kiyuna T; Zhang Y; Zhao M; Hiroshima Y; Nelson SD; Dry SM; Li Y; Yanagawa J; Russell T; Federman N; Singh A; Elliott I; Matsuyama R; Chishima T; Tanaka K; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2017 Jan; 8(5):8035-8042. PubMed ID: 28030831
[TBL] [Abstract][Full Text] [Related]
34. The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Transl Oncol; 2019 Sep; 12(9):1257-1263. PubMed ID: 31299622
[TBL] [Abstract][Full Text] [Related]
35. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations.
Loh AHP; Stewart E; Bradley CL; Chen X; Daryani V; Stewart CF; Calabrese C; Funk A; Miller G; Karlstrom A; Krafcik F; Goshorn DR; Vogel P; Bahrami A; Shelat A; Dyer MA
Cancer Lett; 2019 Feb; 442():262-270. PubMed ID: 30395907
[TBL] [Abstract][Full Text] [Related]
36. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
37. A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
Kiyuna T; Tome Y; Murakami T; Miyake K; Igarashi K; Kawaguchi K; Oshiro H; Higuchi T; Miyake M; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Chawla S; Kanaya F; Eilber FC; Singh SR; Zhao M; Hoffman RM
Biochem Biophys Res Commun; 2018 Nov; 505(3):733-739. PubMed ID: 30292411
[TBL] [Abstract][Full Text] [Related]
38. Chloroquine Combined With Rapamycin Arrests Tumor Growth in a Patient-derived Orthotopic Xenograft (PDOX) Mouse Model of Dedifferentiated Liposarcoma.
Masaki N; Aoki Y; Kubota Y; Obara K; Miyazaki J; Hoffman RM
In Vivo; 2022; 36(6):2630-2637. PubMed ID: 36309387
[TBL] [Abstract][Full Text] [Related]
39. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
[TBL] [Abstract][Full Text] [Related]
40. Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapy.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Aug; 119(8):6598-6603. PubMed ID: 29737543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]